Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

HIV Infection

Free Subscription Articles published in J Virol Retrieve available abstracts of 133 articles: HTML format

Single Articles

June 2026
1. PANCHAPAKESAN A, Joshi AP, Amanullah A, Pargain N, et al
   Enhanced strand transfer and mismatch extension by HIV-1C reverse transcriptase promote sequence motif duplication.
   J Virol. 2026 Jun 4:e0052626. doi: 10.1128/jvi.00526.
   PubMed     Abstract available
   
   
   May 2026
2. FIGUEROA ACOSTA DM, Valencia TR, Li H, Chen BK, et al
   Endocytic motif on HIV-1 Env regulates cleavage status and antibody neutralization of cell-free and cell-to-cell infection.
   J Virol. 2026 May 28:e0154225. doi: 10.1128/jvi.01542.
   PubMed     Abstract available
   
   
   
3. MARTRES D, Montagne T, Pani S, Jeanne N, et al
   Genotypic and phenotypic characteristics of CXCR4-using transmitted/founder HIV-1 envelope glycoproteins.
   J Virol. 2026 May 14:e0006726. doi: 10.1128/jvi.00067.
   PubMed     Abstract available
   
   
   
4. SHI H, Quan P, Hou Y, Wang H, et al
   TRIP12 promotes HIV-1 replication and latency reactivation by stabilizing Tat via USP7-mediated deubiquitination.
   J Virol. 2026 May 13:e0039626. doi: 10.1128/jvi.00396.
   PubMed     Abstract available
   
   
   
5. VINZANT K, Cheshenko N, Pan H, Cutler R, et al
   A cell-impermeable kinase inhibitor uncovers outside-in signaling pathways that promote HIV-1 infection.
   J Virol. 2026 May 11:e0016026. doi: 10.1128/jvi.00160.
   PubMed     Abstract available
   
   
   
6. NIKOLOPOULOS N, Modis Y
   Crystal structure of HERV-K envelope glycoprotein surface subunit.
   J Virol. 2026 May 7:e0019526. doi: 10.1128/jvi.00195.
   PubMed     Abstract available
   
   
   
7. XIE Q, Wang Q, Noettger S, Gosalbez G, et al
   Replication-competent SIVcpz CRISPR screen identifies barriers to successful cross-species transmission.
   J Virol. 2026 May 7:e0031426. doi: 10.1128/jvi.00314.
   PubMed     Abstract available
   
   
   
8. SUOMALAINEN M, Haenseler W, Kolibius J, Pluckthun A, et al
   Transcriptional transactivation turns human iPSC-derived macrophages into an adenovirus-producing cell state.
   J Virol. 2026 May 4:e0039226. doi: 10.1128/jvi.00392.
   PubMed     Abstract available
   
   
   April 2026
9. CHEN H-C
   Is the molecular microenvironment of the latent HIV reservoir predictable using deep learning approaches?
   J Virol. 2026 Apr 30:e0017526. doi: 10.1128/jvi.00175.
   PubMed     Abstract available
   
   
   
10. DA SILVA AMARAL S, Richetta C, Oualid L, Tu NQ, et al
    Effect of TAR hairpin stabilization on HIV-1 reverse transcription.
    J Virol. 2026 Apr 29:e0184025. doi: 10.1128/jvi.01840.
    PubMed     Abstract available
    
    
    
11. SINGH S, Kumar S, Luthra K
    Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.
    J Virol. 2026 Apr 21:e0220225. doi: 10.1128/jvi.02202.
    PubMed     Abstract available
    
    
    
12. SYDENSTRICKER A, Lee D, Voss A, Zheng JH, et al
    HIV transgenic mouse monocytes display increased in vivo migration across the blood-brain barrier associated with increased expression of genes associated with mononuclear leukocyte movement.
    J Virol. 2026 Apr 20:e0206325. doi: 10.1128/jvi.02063.
    PubMed     Abstract available
    
    
    
13. CHENG D, Luo Z, Ning W, Heath SL, et al
    Systemic translocation of Staphylococcus aureus promotes autoimmunity: implications in autoantibody-mediated poor immune reconstitution from antiretroviral therapy in HIV.
    J Virol. 2026 Apr 3:e0196525. doi: 10.1128/jvi.01965.
    PubMed     Abstract available
    
    
    
14. MURPHY T, Kelly M, Shimagaki KS, DeStefanis T, et al
    Dual role of glycosylation in resistance to CD4-binding site broadly neutralizing antibodies.
    J Virol. 2026 Apr 3:e0209325. doi: 10.1128/jvi.02093.
    PubMed     Abstract available
    
    
    March 2026
15. NACHUM GS, Boucher JI, Flynn JM, Quansah P, et al
    Mutational scan of self-cleavage by HIV-1 protease provides new views of a conformationally dynamic mechanism.
    J Virol. 2026 Mar 31:e0222925. doi: 10.1128/jvi.02229.
    PubMed     Abstract available
    
    
    
16. OHKURA S, Osanai H, Shimizu M, Horie M, et al
    Study of retroviral restrictions in a Tadarida bat cell line enlightens specific early blocks and TRIM5 locus multiplication.
    J Virol. 2026 Mar 16:e0192725. doi: 10.1128/jvi.01927.
    PubMed     Abstract available
    
    
    
17. HUANG S, Zhao Y, Phillips S, Warrick JE, et al
    Erratum for Huang et al., "Single-base m(6)A epitranscriptomics reveals novel HIV-1 host interaction targets in primary CD4(+) T cells".
    J Virol. 2026 Mar 9:e0034426. doi: 10.1128/jvi.00344.
    PubMed    
    
    
    
18. ATABEY T, Derking R, Newby ML, Bouhuijs JH, et al
    Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.
    J Virol. 2026 Mar 4:e0148125. doi: 10.1128/jvi.01481.
    PubMed     Abstract available
    
    
    February 2026
19. STERN J, Shepherd RA, Kim Y, Tumpach C, et al
    Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation.
    J Virol. 2026 Feb 25:e0198325. doi: 10.1128/jvi.01983.
    PubMed     Abstract available
    
    
    
20. DOCKEN SS, Macairan A, Schlub TE, Fennessey CM, et al
    Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaques.
    J Virol. 2026 Feb 18:e0148525. doi: 10.1128/jvi.01485.
    PubMed     Abstract available
    
    
    January 2026
21. MCMAHON EK, Lochner JS, Lynch RM, Bosque A, et al
    Retinoids enhance NK effector function against HIV-infected CD4 T cells.
    J Virol. 2026 Jan 27:e0162025. doi: 10.1128/jvi.01620.
    PubMed     Abstract available
    
    
    
22. BISWAS U, Bernal C, Wang R, DeStefano JJ, et al
    Correction for Biswas et al., "A novel aptamer-based dNTP assay reveals that intact HIV virions are highly stable and do not contain enough dNTPs to support DNA synthesis".
    J Virol. 2026 Jan 7:e0202825. doi: 10.1128/jvi.02028.
    PubMed    
    
    
    December 2025
23. KREIG JAF, Wahl A, Fernandes E, Honeycutt JB, et al
    The decay of HIV under anti-retroviral therapy is biphasic even in humanized mice with just T cells.
    J Virol. 2025 Dec 30:e0132125. doi: 10.1128/jvi.01321.
    PubMed     Abstract available
    
    
    
24. DIAZ-SALINAS MA, Benlarbi M, Chatterjee D, Nayrac M, et al
    Conformational dynamics of the HIV-1 envelope glycoprotein from CRF01_AE is associated with susceptibility to antibody-dependent cellular cytotoxicity.
    J Virol. 2025 Dec 9:e0166725. doi: 10.1128/jvi.01667.
    PubMed     Abstract available
    
    
    
25. YANG T, Chen M, Zhou M, Deng X, et al
    The crosstalk between ubiquitination and GlcNAcylation of CHAF1A regulates HIV-1 latency and reactivation.
    J Virol. 2025 Dec 3:e0151825. doi: 10.1128/jvi.01518.
    PubMed     Abstract available
    
    
    
26. WANG Y, Fu S, Wang X, Gao G, et al
    Phosphorylation of Shiftless by casein kinase 1 delta/epsilon is required for its antiviral activity.
    J Virol. 2025 Dec 2:e0186425. doi: 10.1128/jvi.01864.
    PubMed     Abstract available
    
    
    
27. BALDINO AM, Mumby MJ, Edgar CR, Olabode AS, et al
    Ancestral reconstruction supports that loss of Nef-mediated T cell modulation coincided with the emergence of pathogenic lentiviruses.
    J Virol. 2025 Dec 2:e0154825. doi: 10.1128/jvi.01548.
    PubMed     Abstract available
    
    
    November 2025
28. WEBB NE, Gorman MJ, Parker LJ, Jung W, et al
    The functional antibody landscape in HIV post-treatment controllers is heterogeneous.
    J Virol. 2025 Nov 28:e0179025. doi: 10.1128/jvi.01790.
    PubMed     Abstract available
    
    
    
29. ANANG S, Zhang S, Ennis A, Ding H, et al
    Characterization of full-length and cytoplasmic tail-truncated envelope glycoproteins incorporated into human immunodeficiency virus (HIV-1) virions and virus-like particles.
    J Virol. 2025 Nov 26:e0158525. doi: 10.1128/jvi.01585.
    PubMed     Abstract available
    
    
    
30. LODGE R, Kmiec D, Kirchhoff F, Cohen EA, et al
    HIV-2 glycoproteins upregulate microRNAs 25 and 93 to counter the MARCH1 antiviral effect in macrophages.
    J Virol. 2025 Nov 24:e0166325. doi: 10.1128/jvi.01663.
    PubMed     Abstract available
    
    
    
31. SHI M, Chen R, Wu T, Liao Y, et al
    Single-cell transcriptome profiling reveals immunological fitness of HIV long-term non-progressors.
    J Virol. 2025 Nov 24:e0159725. doi: 10.1128/jvi.01597.
    PubMed     Abstract available
    
    
    
32. GOPAL K, Burnett C, Kharytonchyk S, Emery A, et al
    RNA splicing patterns contribute to burst size variation among HIV-1-infected Jurkat cell clones.
    J Virol. 2025 Nov 24:e0133425. doi: 10.1128/jvi.01334.
    PubMed     Abstract available
    
    
    
33. ZUROWSKA K, Dzhivhuho G, Grabski D, Rekosh D, et al
    Characterization of HERV-K (HML-2) Rec proteins encoded in the human genome and their post-transcriptional function.
    J Virol. 2025 Nov 18:e0151525. doi: 10.1128/jvi.01515.
    PubMed     Abstract available
    
    
    
34. JAMIESON PJ, Shen X, Abu-Shmais AA, Wasdin PT, et al
    Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.
    J Virol. 2025 Nov 10:e0125625. doi: 10.1128/jvi.01256.
    PubMed     Abstract available
    
    
    
35. MATHUR T, Ahmed S, Parthasarathy D, Herschhorn A, et al
    Highly efficient production of HIV-1(AD8) gp120 in mammalian cells.
    J Virol. 2025 Nov 7:e0135925. doi: 10.1128/jvi.01359.
    PubMed     Abstract available
    
    
    October 2025
36. HUANG S, Zhao Y, Phillips S, Warrick JE, et al
    Single-base m(6)A epitranscriptomics reveals novel HIV-1 host interaction targets in primary CD4(+) T cells.
    J Virol. 2025 Oct 14:e0153625. doi: 10.1128/jvi.01536.
    PubMed     Abstract available
    
    
    
37. MEDICA S, Diggins NL, Denton M, Turner RL, et al
    Human cytomegalovirus UL78 is a nuclear-localized GPCR necessary for efficient reactivation from latent infection in CD34(+) hematopoietic progenitor cells.
    J Virol. 2025 Oct 8:e0140225. doi: 10.1128/jvi.01402.
    PubMed     Abstract available
    
    
    
38. MITCHELL JK, Mastrodomenico V, Hartnett J, Heelan WJ, et al
    A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification of virus neutralization and antibody-dependent enhancement.
    J Virol. 2025 Oct 8:e0099125. doi: 10.1128/jvi.00991.
    PubMed     Abstract available
    
    
    September 2025
39. VACA CC, Hudson H, Clerc I, Song C, et al
    HIV proviral transcription and infectivity are enhanced by neddylation.
    J Virol. 2025 Sep 30:e0096825. doi: 10.1128/jvi.00968.
    PubMed     Abstract available
    
    
    
40. BRANT AC, Hu Z, Chen AZ, Majerciak V, et al
    Discontinuous template switching generates coronavirus subgenomic RNAs from the 3' viral genome end by 5' to 3' transcription.
    J Virol. 2025 Sep 25:e0143825. doi: 10.1128/jvi.01438.
    PubMed     Abstract available
    
    
    
41. SHAO Q, Wang Y, Hildreth JEK, Liu B, et al
    Correction for Shao et al., "Polyubiquitination of APOBEC3G Is Essential for Its Degradation by HIV-1 Vif".
    J Virol. 2025 Sep 23:e0136825. doi: 10.1128/jvi.01368.
    PubMed    
    
    
    
42. KOMA T, Kotani O, Kamba K, Miyakawa K, et al
    Positive correlation between structural disorder of the HIV-1 Gag N-terminal segment and progeny virus particle formation.
    J Virol. 2025 Sep 16:e0088725. doi: 10.1128/jvi.00887.
    PubMed     Abstract available
    
    
    
43. JOSEPH R, Marais G, Iranzadeh I, Alisoltani A, et al
    Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2.
    J Virol. 2025 Sep 5:e0078025. doi: 10.1128/jvi.00780.
    PubMed     Abstract available
    
    
    August 2025
44. DAVIS DA, Astter Y, Treco EN, Shrestha P, et al
    Caspase cleavage of Kaposi sarcoma-associated herpesvirus proteins: a role for K5 in preventing caspase-mediated cell death during lytic replication.
    J Virol. 2025 Aug 29:e0062225. doi: 10.1128/jvi.00622.
    PubMed     Abstract available
    
    
    
45. CHATURBHUJ DN, Sliepen K, Cupo A, Steinberg B, et al
    A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.
    J Virol. 2025 Aug 27:e0091325. doi: 10.1128/jvi.00913.
    PubMed     Abstract available
    
    
    
46. MESA KA, Li SW, Hutchinson JM, O'Rourke S, et al
    Parallel evolution of the elite neutralizer phenotype in divergent HIV-1 clades.
    J Virol. 2025 Aug 21:e0043325. doi: 10.1128/jvi.00433.
    PubMed     Abstract available
    
    
    
47. ZHANG H, Deng X, Dai R, Fu J, et al
    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.
    J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688.
    PubMed     Abstract available
    
    
    
48. MUELLER AL, Lamcaj S, Garforth S, Hiner C, et al
    T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.
    J Virol. 2025 Aug 5:e0018825. doi: 10.1128/jvi.00188.
    PubMed     Abstract available
    
    
    July 2025
49. DING S, Tauzin A, Pinto-Santini D, Dasgupta S, et al
    CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection.
    J Virol. 2025 Jul 21:e0085825. doi: 10.1128/jvi.00858.
    PubMed     Abstract available
    
    
    
50. BISWAS U, Bernal C, Wang R, DeStefano JJ, et al
    A novel aptamer-based dNTP assay reveals that intact HIV virions are highly stable and do not contain enough dNTPs to support DNA synthesis.
    J Virol. 2025 Jul 15:e0056425. doi: 10.1128/jvi.00564.
    PubMed     Abstract available
    
    
    
51. SUN Y, Yang C, Liu P, Cong Z, et al
    Novel insights into immune checkpoints in HIV/SHIV infection: from SHIV(SF162P3)-infected elite controllers to therapeutic strategy.
    J Virol. 2025 Jul 10:e0078525. doi: 10.1128/jvi.00785.
    PubMed     Abstract available
    
    
    
52. JANSSENS J, Isbell C, Kim SJ, Wedrychowski A, et al
    Differential decreases in various HIV DNA regions and HIV transcripts after ART initiation during chronic infection.
    J Virol. 2025 Jul 8:e0068325. doi: 10.1128/jvi.00683.
    PubMed     Abstract available
    
    
    
53. TORGBOR C, Thorley-Lawson DA, Moormann AM
    Epstein-Barr virus-infected tonsillar marginal zone B cells in vivo as a precursor for immunosuppression-related B-cell lymphoma.
    J Virol. 2025 Jul 8:e0105124. doi: 10.1128/jvi.01051.
    PubMed     Abstract available
    
    
    June 2025
54. ISMAIL SD, Sebaa S, Abrahams B, Nason MC, et al
    The role of Nef in the long-term persistence of the replication-competent HIV reservoir in South African women.
    J Virol. 2025 Jun 24:e0021725. doi: 10.1128/jvi.00217.
    PubMed     Abstract available
    
    
    
55. COTTIGNIES-CALAMARTE A, Marteau F, He F, Belouzard S, et al
    Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response.
    J Virol. 2025 Jun 12:e0039425. doi: 10.1128/jvi.00394.
    PubMed     Abstract available
    
    
    
56. SCHIFFER JT, Mudd JC, Antar AAR, Spivak AM, et al
    Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.
    J Virol. 2025 Jun 4:e0071425. doi: 10.1128/jvi.00714.
    PubMed     Abstract available
    
    
    May 2025
57. SUTAR J, Jayal P, Mullick R, Chaudhary S, et al
    Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies.
    J Virol. 2025 May 16:e0000825. doi: 10.1128/jvi.00008.
    PubMed     Abstract available
    
    
    
58. GREBER UF
    Clicking viruses-with chemistry toward mechanisms in infection.
    J Virol. 2025 May 14:e0047125. doi: 10.1128/jvi.00471.
    PubMed     Abstract available
    
    
    
59. NIKOLAITCHIK OA, Chameettachal A, Islam S, Cheng Z, et al
    How to recover from a bad start: adaptation of HIV-1 transcription start site mutants during serial passaging in culture.
    J Virol. 2025 May 7:e0015925. doi: 10.1128/jvi.00159.
    PubMed     Abstract available
    
    
    April 2025
60. FAN T-J, Xie C, Li L, Jin X, et al
    HIV-1 Nef activates proviral DNA transcription by recruiting Src kinase to phosphorylate host protein Nef-associated factor 1 to compromise its viral restrictive function.
    J Virol. 2025 Apr 24:e0028025. doi: 10.1128/jvi.00280.
    PubMed     Abstract available
    
    
    
61. RADFORD CE, Bloom JD
    Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains.
    J Virol. 2025 Apr 22:e0019525. doi: 10.1128/jvi.00195.
    PubMed     Abstract available
    
    
    
62. LARROUS P, Garnier C, Morel M, Martin MM, et al
    Deciphering lentiviral Vpr/Vpx determinants required for HUSH and SAMHD1 antagonism highlights the molecular plasticity of these evolutionary conflicts.
    J Virol. 2025 Apr 22:e0019825. doi: 10.1128/jvi.00198.
    PubMed     Abstract available
    
    
    
63. MOORAD R, Peng A, Landis J, Pluta LJ, et al
    Genome evolution of Kaposi sarcoma-associated herpesvirus (KSHV).
    J Virol. 2025 Apr 16:e0195024. doi: 10.1128/jvi.01950.
    PubMed     Abstract available
    
    
    
64. GROVES NS, Clark AR, Aguilar RS, Hikichi Y, et al
    A monomeric envelope glycoprotein cytoplasmic tail is sufficient for HIV-1 Gag lattice trapping and incorporation.
    J Virol. 2025 Apr 15:e0210524. doi: 10.1128/jvi.02105.
    PubMed     Abstract available
    
    
    
65. HUANG Y, Liang G, Wang T, Ma Y, et al
    Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals.
    J Virol. 2025 Apr 10:e0228924. doi: 10.1128/jvi.02289.
    PubMed     Abstract available
    
    
    
66. WU C, Johnson NM, Yu S, Lo AS, et al
    Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy.
    J Virol. 2025 Apr 10:e0193324. doi: 10.1128/jvi.01933.
    PubMed     Abstract available
    
    
    
67. CHAUDHURI E, Jang S, Chakraborty R, Radhakrishnan R, et al
    CPSF6 promotes HIV-1 preintegration complex function.
    J Virol. 2025 Apr 9:e0049025. doi: 10.1128/jvi.00490.
    PubMed     Abstract available
    
    
    
68. VIOX EG, Richard J, Grandea AG 3rd, Nguyen K, et al
    Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques.
    J Virol. 2025 Apr 7:e0006225. doi: 10.1128/jvi.00062.
    PubMed     Abstract available
    
    
    March 2025
69. CHATTERJEE D, Niu L, Medjahed H, Ding S, et al
    A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120.
    J Virol. 2025 Mar 27:e0226724. doi: 10.1128/jvi.02267.
    PubMed     Abstract available
    
    
    
70. YAN H, Gao Y, Zhu Y, Chong H, et al
    Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency.
    J Virol. 2025 Mar 25:e0201824. doi: 10.1128/jvi.02018.
    PubMed     Abstract available
    
    
    
71. VICTORIA S, Leyens J, Meckes LM, Vavouras Syrigos G, et al
    CD4+ T cells facilitate replication of primary HIV-1 strains in macrophages and formation of macrophage internal virus-containing compartments.
    J Virol. 2025 Mar 25:e0018225. doi: 10.1128/jvi.00182.
    PubMed     Abstract available
    
    
    
72. HSIEH S-H, Huang K-J, Wang C-T
    A virus-like particle assembly system for probing the HIV-1 Gag-Pol dimerization domain: supporting evidence for reverse transcriptase involvement in protease activation by influencing Gag-Pol/Gag-Pol interaction.
    J Virol. 2025 Mar 12:e0223624. doi: 10.1128/jvi.02236.
    PubMed     Abstract available
    
    
    
73. TURNER A-MW, Bashore FM, Falcinelli SD, Fox JA, et al
    BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells.
    J Virol. 2025 Mar 11:e0177724. doi: 10.1128/jvi.01777.
    PubMed     Abstract available
    
    
    
74. GC K, Lesko S, Emery A, Burnett C, et al
    HIV-1 single-transcription start-site mutants display complementary replication functions that are restored by reversion.
    J Virol. 2025 Mar 4:e0213924. doi: 10.1128/jvi.02139.
    PubMed     Abstract available
    
    
    
75. JANEVSKA M, Witkowski W, Vermeire J, Borowicz M, et al
    Impairment of endocytosis-related factors FNBP1L, ARHGAP24, and ATP6V1B1 increases HIV-1 entry into dendritic cells.
    J Virol. 2025 Mar 3:e0206624. doi: 10.1128/jvi.02066.
    PubMed     Abstract available
    
    
    February 2025
76. GOLAS G, Park BS, Wong SW
    Glycoproteins gM and gN are indispensable factors for rhesus macaque rhadinovirus replication and spread but can be reconstituted by KSHV chimeras.
    J Virol. 2025 Feb 25:e0192224. doi: 10.1128/jvi.01922.
    PubMed     Abstract available
    
    
    
77. GUERRERO JF, Zimdars LL, Bruce JW, Becker JT, et al
    Single-cell delineation of strain-specific HIV-1 Vif activities using dual reporter sensor cells and live cell imaging.
    J Virol. 2025 Feb 25:e0157924. doi: 10.1128/jvi.01579.
    PubMed     Abstract available
    
    
    
78. XU M, Hu H, Yang W, Zhang J, et al
    FBXO45 restricts HIV-1 replication by inducing SQSTM1/p62-mediated autophagic degradation of Tat.
    J Virol. 2025 Feb 12:e0191224. doi: 10.1128/jvi.01912.
    PubMed     Abstract available
    
    
    
79. WILLIAMS EP, Xue Y, Vogel P, Yang D, et al
    The antiviral BDGR-49 provides protection from lethal, neurotropic Venezuelan equine encephalitis virus intranasal infection in mice.
    J Virol. 2025 Feb 12:e0167924. doi: 10.1128/jvi.01679.
    PubMed     Abstract available
    
    
    
80. MITCHELL JL, Buranapraditkun S, Gantner P, Takata H, et al
    Activation of CXCR3(+) Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development.
    J Virol. 2025 Feb 11:e0153224. doi: 10.1128/jvi.01532.
    PubMed     Abstract available
    
    
    
81. LI M, Yu F, Zhu B, Xiao J, et al
    Interactions between human immunodeficiency virus and human endogenous retroviruses.
    J Virol. 2025 Feb 7:e0231924. doi: 10.1128/jvi.02319.
    PubMed     Abstract available
    
    
    
82. ANG CG, Hyatt NL, Le Minh G, Gupta M, et al
    Conformational activation and disulfide exchange in HIV-1 Env induce cell-free lytic/fusogenic transformation and enhance infection.
    J Virol. 2025 Feb 6:e0147124. doi: 10.1128/jvi.01471.
    PubMed     Abstract available
    
    
    
83. HUDSON A, Wu P, Kroll KW, Hueber B, et al
    Longitudinal analysis of rhesus macaque metabolome during acute SIV infection reveals disruption in broad metabolite classes.
    J Virol. 2025 Feb 6:e0163424. doi: 10.1128/jvi.01634.
    PubMed     Abstract available
    
    
    
84. JANSSENS J, Wedrychowski A, Kim SJ, Isbell C, et al
    Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection.
    J Virol. 2025 Feb 5:e0143124. doi: 10.1128/jvi.01431.
    PubMed     Abstract available
    
    
    
85. PASCOE RD, Kim Y, Rhodes A, Ong J, et al
    Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir.
    J Virol. 2025 Feb 4:e0167624. doi: 10.1128/jvi.01676.
    PubMed     Abstract available
    
    
    January 2025
86. KAJASTE-RUDNITSKI A, Marelli SS, Pultrone C, Pertel T, et al
    Correction for Kajaste-Rudnitski et al., "TRIM22 Inhibits HIV-1 Transcription Independently of Its E3 Ubiquitin Ligase Activity, Tat, and NF-kappaB-Responsive Long Terminal Repeat Elements".
    J Virol. 2025 Jan 27:e0207124. doi: 10.1128/jvi.02071.
    PubMed    
    
    
    
87. ARA A, Love RP, Follack TB, Ahmed KA, et al
    Erratum for Ara et al., "Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G".
    J Virol. 2025 Jan 16:e0220424. doi: 10.1128/jvi.02204.
    PubMed    
    
    
    
88. FAYYAZ S, Lotke R, Haussmann I, Petersen M, et al
    Reactivation of latent HIV-1 by the glucocorticoid receptor modulator AZD9567.
    J Virol. 2025 Jan 16:e0188624. doi: 10.1128/jvi.01886.
    PubMed     Abstract available
    
    
    
89. COHEN P, Lambson BE, Mkhize NN, Moodley C, et al
    Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.
    J Virol. 2025 Jan 16:e0173024. doi: 10.1128/jvi.01730.
    PubMed     Abstract available
    
    
    
90. LICHON DM, LoMascolo NJ, Mounce BC, Campbell EM, et al
    Microtubule acetylation is not required for HIV-1 infection or TRIM69-mediated restriction of HIV-1 infection.
    J Virol. 2025 Jan 13:e0102624. doi: 10.1128/jvi.01026.
    PubMed     Abstract available
    
    
    December 2024
91. COUNCIL OD, Tyers L, Moeser M, Sondgeroth A, et al
    The persistent pool of HIV-1-infected cells is formed episodically during untreated infection.
    J Virol. 2024 Dec 26:e0097924. doi: 10.1128/jvi.00979.
    PubMed     Abstract available
    
    
    
92. GABA A, Yousefi M, Bhattacharjee S, Chelico L, et al
    Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction.
    J Virol. 2024 Dec 23:e0160624. doi: 10.1128/jvi.01606.
    PubMed     Abstract available
    
    
    
93. CHEN C, Zhong Z, Zhang W, Xia B, et al
    Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation.
    J Virol. 2024 Dec 18:e0117324. doi: 10.1128/jvi.01173.
    PubMed     Abstract available
    
    
    
94. CHEN K, Zhou B, Wang X, Yang G, et al
    Equine lentivirus Gag protein degrades mitochondrial antiviral signaling protein via the E3 ubiquitin ligase Smurf1.
    J Virol. 2024 Dec 12:e0169124. doi: 10.1128/jvi.01691.
    PubMed     Abstract available
    
    
    
95. CUI W, Wang H, Gao Y, Zhang X, et al
    Deubiquitinase USP37 enhances the anti-HIV-2/SIV ability of the host restriction factor SAMHD1.
    J Virol. 2024 Dec 10:e0185824. doi: 10.1128/jvi.01858.
    PubMed     Abstract available
    
    
    
96. TAKAHAMA S, Washizaki A, Okamura T, Kitamura S, et al
    The quality of SIV-specific fCD8 T cells limits SIV RNA production in Tfh cells during antiretroviral therapy.
    J Virol. 2024 Dec 6:e0081224. doi: 10.1128/jvi.00812.
    PubMed     Abstract available
    
    
    November 2024
97. DING H, Nguyen HT, Li W, Deshpande A, et al
    Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.
    J Virol. 2024 Nov 7:e0172024. doi: 10.1128/jvi.01720.
    PubMed     Abstract available
    
    
    
98. STEVENS CS, Carmichael JC, Watkinson R, Kowdle S, et al
    A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing.
    J Virol. 2024 Nov 4:e0083224. doi: 10.1128/jvi.00832.
    PubMed     Abstract available
    
    
    October 2024
99. PADRON A, Dwivedi R, Chakraborty R, Prakash P, et al
    Cyclophilin A facilitates HIV-1 integration.
    J Virol. 2024 Oct 31:e0094724. doi: 10.1128/jvi.00947.
    PubMed     Abstract available
    
    
    
100. HE W-Q, Pang W, Li N, Li A-Q, et al
     IFI27 inhibits HIV-1 replication by degrading Gag protein through the ubiquitin-proteasome pathway.
     J Virol. 2024 Oct 30:e0135624. doi: 10.1128/jvi.01356.
     PubMed     Abstract available
     
     
     
101. LADINSKY MS, Zhu L, Ullah I, Uchil PD, et al
     Electron tomography visualization of HIV-1 virions trapped by fusion inhibitors to host cells in infected tissues.
     J Virol. 2024 Oct 30:e0143224. doi: 10.1128/jvi.01432.
     PubMed     Abstract available
     
     
     
102. HOGAN VA, Harmon J, Cid-Rosas M, Hall LR, et al
     Conserved residues of the immunosuppressive domain of MLV are essential for regulating the fusion-critical SU-TM disulfide bond.
     J Virol. 2024 Oct 29:e0098924. doi: 10.1128/jvi.00989.
     PubMed     Abstract available
     
     
     September 2024
103. CHENG Z, Islam S, Kanlong JG, Sheppard M, et al
     Translation of HIV-1 unspliced RNA is regulated by 5' untranslated region structure.
     J Virol. 2024 Sep 24:e0116024. doi: 10.1128/jvi.01160.
     PubMed     Abstract available
     
     
     
104. PINCUS SH, Cole FM, Ober K, Tokmina-Lukaszewska M, et al
     Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate.
     J Virol. 2024 Sep 16:e0064724. doi: 10.1128/jvi.00647.
     PubMed     Abstract available
     
     
     
105. JANEVSKA M, Cammaert T, Naessens E, Verhasselt B, et al
     A cGAS-mediated type I interferon response in human CD4+ T cells depends on productive infection and is conserved over HIV types and strains.
     J Virol. 2024 Sep 13:e0087724. doi: 10.1128/jvi.00877.
     PubMed     Abstract available
     
     
     
106. ZANKHARIA U, Yi Y, Lu F, Vladimirova O, et al
     HIV-induced RSAD2/Viperin supports sustained infection of monocyte-derived macrophages.
     J Virol. 2024 Sep 11:e0086324. doi: 10.1128/jvi.00863.
     PubMed     Abstract available
     
     
     
107. MARCHITTO L, Richard J, Prevost J, Tauzin A, et al
     The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.
     J Virol. 2024 Sep 9:e0101624. doi: 10.1128/jvi.01016.
     PubMed     Abstract available
     
     
     
108. ZHANG S, Anang S, Zhang Z, Nguyen HT, et al
     Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs.
     J Virol. 2024 Sep 9:e0063124. doi: 10.1128/jvi.00631.
     PubMed     Abstract available
     
     
     
109. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
     Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
     J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
     PubMed     Abstract available
     
     
     
110. TAUZIN A, Marchitto L, Belanger E, Benlarbi M, et al
     Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.
     J Virol. 2024 Sep 4:e0096024. doi: 10.1128/jvi.00960.
     PubMed     Abstract available
     
     
     
111. ZHANG W, Nilles TL, Bream JH, Li H, et al
     Breadth and polyfunctionality of T cell responses to human cytomegalovirus in men who have sex with men: relationship with HIV infection and frailty.
     J Virol. 2024 Sep 4:e0116724. doi: 10.1128/jvi.01167.
     PubMed     Abstract available
     
     
     August 2024
112. BRACKENRIDGE S, John N, He W, Fruh K, et al
     Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.
     J Virol. 2024 Aug 29:e0120624. doi: 10.1128/jvi.01206.
     PubMed     Abstract available
     
     
     
113. ZHANG Y, Zhang M, Wu H, Wu X, et al
     Afucosylated anti-EBOV antibody MIL77-3 engages sGP to elicit NK cytotoxicity.
     J Virol. 2024 Aug 20:e0068524. doi: 10.1128/jvi.00685.
     PubMed     Abstract available
     
     
     
114. BARBOSA BOMFIM CC, Genin H, Cottoignies-Callamarte A, Gallois-Montbrun S, et al
     CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients.
     J Virol. 2024 Aug 20:e0012824. doi: 10.1128/jvi.00128.
     PubMed     Abstract available
     
     
     
115. MUECKSCH F, Klaus S, Laketa V, Muller B, et al
     Probing Gag-Env dynamics at HIV-1 assembly sites using live-cell microscopy.
     J Virol. 2024 Aug 13:e0064924. doi: 10.1128/jvi.00649.
     PubMed     Abstract available
     
     
     
116. MU Z, Whitley J, Martik D, Sutherland L, et al
     Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
     J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137.
     PubMed     Abstract available
     
     
     July 2024
117. ZHOU M, Yang T, Yuan M, Li X, et al
     ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latency.
     J Virol. 2024 Jul 31:e0003524. doi: 10.1128/jvi.00035.
     PubMed     Abstract available
     
     
     
118. NELSON GW, van Duijn J, Yuki Y, Pau MG, et al
     Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
     J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281.
     PubMed     Abstract available
     
     
     
119. REYES BALLISTA JM, Hoover AJ, Noble JT, Acciani MD, et al
     Chikungunya virus release is reduced by TIM-1 receptors through binding of envelope phosphatidylserine.
     J Virol. 2024 Jul 15:e0077524. doi: 10.1128/jvi.00775.
     PubMed     Abstract available
     
     
     June 2024
120. KUSE N, Noyori O, Takahashi N, Zhang Y, et al
     Recognition of HIV-1-infected fibrocytes lacking Nef-mediated HLA-B downregulation by HIV-1-specific T cells.
     J Virol. 2024 Jun 28:e0079124. doi: 10.1128/jvi.00791.
     PubMed     Abstract available
     
     
     
121. ROESMANN F, Sertznig H, Klaassen K, Wilhelm A, et al
     The interferon-regulated host factor hnRNPA0 modulates HIV-1 production by interference with LTR activity, mRNA trafficking, and programmed ribosomal frameshifting.
     J Virol. 2024 Jun 20:e0053424. doi: 10.1128/jvi.00534.
     PubMed     Abstract available
     
     
     
122. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
     Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
     J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
     PubMed     Abstract available
     
     
     May 2024
123. NAZZIWA J, Andrews SM, Hou MM, Bruhn CAW, et al
     Higher HIV-1 evolutionary rate is associated with cytotoxic T lymphocyte escape mutations in infants.
     J Virol. 2024 May 30:e0007224. doi: 10.1128/jvi.00072.
     PubMed     Abstract available
     
     
     
124. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
     Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.
     J Virol. 2024 May 24:e0033524. doi: 10.1128/jvi.00335.
     PubMed    
     
     
     
125. RAHMBERG AR, Markowitz TE, Mudd JC, Ortiz AM, et al
     SIV infection and ARV treatment reshape the transcriptional and epigenetic profile of naive and memory T cells in vivo.
     J Virol. 2024 May 23:e0028324. doi: 10.1128/jvi.00283.
     PubMed     Abstract available
     
     
     
126. WEBB GM, Pessoa CT, McCullen AJ, Hwang JM, et al
     Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.
     J Virol. 2024 May 22:e0027324. doi: 10.1128/jvi.00273.
     PubMed     Abstract available
     
     
     
127. VERBEEK R, Vandekerckhove L, Van Cleemput J
     Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research.
     J Virol. 2024 May 8:e0043724. doi: 10.1128/jvi.00437.
     PubMed     Abstract available
     
     
     April 2024
128. PERSAUD AT, Khela J, Fernandes C, Chaphekar D, et al
     Virion-incorporated CD14 enables HIV-1 to bind LPS and initiate TLR4 signaling in immune cells.
     J Virol. 2024 Apr 25:e0036324. doi: 10.1128/jvi.00363.
     PubMed     Abstract available
     
     
     
129. YANG Q, Wang J, Chen Z
     Conditional splicing system for tight control of viral overlapping genes.
     J Virol. 2024;98:e0024224.
     PubMed     Abstract available
     
     
     March 2024
130. VON MALTITZ P, Wettstein L, Weil T, Schommers P, et al
     Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies.
     J Virol. 2024 Mar 19:e0119023. doi: 10.1128/jvi.01190.
     PubMed     Abstract available
     
     
     
131. TWENTYMAN J, Emerman M, Ohainle M
     Capsid-dependent lentiviral restrictions.
     J Virol. 2024 Mar 18:e0030824. doi: 10.1128/jvi.00308.
     PubMed     Abstract available
     
     
     February 2024
132. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
     A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
     J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
     PubMed     Abstract available
     
     
     September 2023
133. HORVATH RM, Brumme ZL, Sadowski I
     CDK8 inhibitors antagonize HIV-1 reactivation and promote provirus latency in T cells.
     J Virol. 2023;97:e0092323.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum